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98Enhanced Expression of Genes Related to
Xenobiotic Metabolism in the Skin of
Patients with Atopic Dermatitis but Not
with Ichthyosis Vulgaris
Stefan Blunder1,5, Sulev Ko˜ks2,5, Gea Ko˜ks2, Ene Reimann2, Hubert Hackl3, Robert Gruber1,4,
Verena Moosbrugger-Martinz1, Matthias Schmuth1 and Sandrine Dubrac1Previous transcriptome analyses underscored the importance of immunological and skin barrier abnormalities
in atopic dermatitis (AD). We sought to identify pathogenic pathways involved in AD by comparing the tran-
scriptomes of AD patients stratified for filaggrin (FLG)-null mutations to those of both healthy donors and
patients with ichthyosis vulgaris. We applied RNA sequencing to analyze the whole transcriptome of nonle-
sional skin. We found that 607 genes (476 up-regulated and 131 down-regulated by >2-fold) and 193 genes (172
up-regulated and 21 down-regulated by >2-fold) were differentially expressed when all AD or ichthyosis vul-
garis patients were compared with healthy donors, respectively. Expression of genes involved in RNA/protein
turnover and adenosine triphosphate synthesis, as well as genes involved in cell death, response to oxidative
stress, DNA damage/repair, and autophagy, were significantly enriched in AD skin and, to a lesser extent, in
ichthyosis vulgaris skin. FLG-null mutations appear to hardly interfere with current observations. Genes related
to xenobiotic metabolism were up-regulated in AD skin only, as were genes related to arachidonic, linoleic, and
a-linolenic acid metabolism. Thus, this work newly links AD pathogenesis to aberrant expression of genes
related to xenobiotic metabolism.
Journal of Investigative Dermatology (2018) 138, 98e108; doi:10.1016/j.jid.2017.08.036INTRODUCTION
Atopic dermatitis (AD) is one of themost common dermatoses,
affecting 2e5% of adults and 10e20% of children worldwide
(International Study of Asthma and Allergies in Childhood
Steering Committee, 1998). AD is characterized by pruritus,
eczematous lesions, and skin dryness and is commonly asso-
ciated with allergic conditions such as allergic rhinitis and
asthma (Leung and Guttman-Yassky, 2014). It was long
assumed that most childhood cases of AD undergo full
remission before adolescence (Bieber, 2008). However, data
published in 2011 show that, in the United States, 10.7% of
children and 10.2% of adults are affected by AD, suggesting
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an open access artadulthood (Shaw et al., 2011). Similarly in Europe, 5e20% of
all school children and 2e18% of all adults have AD, thus
confirming the same clinical pattern (Asher et al., 2006; Flohr
and Mann, 2014; International Study of Asthma and Allergies
in Childhood Steering Committee, 1998; Harrop et al., 2007;
Odhiambo et al., 2009).
The pathogenesis of AD is not yet fully understood, but there
is consensus that immune hyper-responsiveness and epidermal
barrier impairment are predominant etiologic factors (Leung
and Guttman-Yassky, 2014). Several studies have linked
impaired epidermal barrier function resulting from null muta-
tions in the filaggrin (FLG) gene, which give rise to ichthyosis
vulgaris (IV) as amajor driver of the development of AD (Palmer
et al., 2006; Weidinger et al., 2006). FLG is located on chro-
mosome 1 in the epidermal differentiation complex, a region
carrying various genes encoding epidermal structural proteins
and repeatedly found tobe linked toAD (Hoffjan andStemmler,
2007). However, in various AD patient cohorts, IgE-mediated
allergic reactions, irritants, or psychosomatic disorders appear
to be of major importance (Leung and Guttman-Yassky, 2014).
Moreover, air pollutants, endocrine disruptors, or components
of cigarette smoke are positively associated with AD (Ahn,
2014). Hence, the deleterious impact of the environment on
the course of AD may have recently increased (Hidaka et al.,
2017; Kabashima et al., 2016).
Previous transcriptome analyses have been carried out in
lesional versus nonlesional skin of adults with AD not strat-
ified for FLG-null mutations and in nonlesional skin of infants
stratified for FLG both refining and extending previous datas. Published by Elsevier, Inc. on behalf of the Society for Investigative Dermatology. This is
icle under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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RNA Sequencing in AD and IV Skinobtained by microarray analyses (Ewald et al., 2015). Paller
et al. (2016) have recently shown that patients with ich-
thyosis, including congenital ichthyosiform erythroderma,
lamellar ichthyosis, epidermolytic ichthyosis, and Netherton
syndrome exhibit a T helper type 17 skin immune profile,
similar to that observed in patients with psoriasis. Data on IV,
which is the most frequent form of ichthyosis, are still
missing; however, inclusion of IV skin is clearly of impor-
tance to better understand the pathogenesis of AD, because
patients with IV, despite having FLGmutations, do not exhibit
overt skin inflammation. Thus, comparing results obtained
from skin of AD patients with those from skin of IV patients
might identify previously unrecognized pathways involved in
the transition from noninflammatory dry and scaly skin to
nonlesional AD skin, including the proinflammatory mech-
anisms involved in this sequence. And although emollients,
immunosuppressants, and anxiolytic drugs do ameliorate
AD, they are not curative (Hashizume and Takigawa, 2006).
Therefore, elucidation of as-yet unexplored mechanisms
involved in the pathogenesis and maintenance of AD could
lead to new treatments and potential prophylactic strategies.
With this goal, we aimed to identify potential pathways
involved in the development of AD by comparing nonle-
sional AD skin from patients with or without FLG-null mu-
tations with skin from patients with IV.
RESULTS
Gene expression signature in AD and IV patient skin is
different, regardless of FLG mutations
We performed global transcriptional profiling to identify gene
expression patterns that could distinguish AD patients with or
without FLG-null mutations from control subjects and IV pa-
tients. By this approach, we also expected to uncover new
pathways involved in AD pathogenesis. We used skin biopsy
samples from four patient groups to carry out the analyses:
controls (Ctrl wild type [WT]/WT), AD patients with or without
FLG mutations (AD FLG MUT and AD WT/WT, respectively),
and patients with IV presenting a dry and scaly skin without
signs of overt inflammation. Furthermore, to avoid variations
related to age or disease background, we recruited only adult
patientswith a history of AD since childhood.Moreover, to rule
out differences due to tissue heterogeneity, the biopsy samples
of nonlesional skin were taken from the same body region. We
performed RNA sequencing in whole skin from a total of 20
patients and 9 healthy adult control subjects (cohort I) (see
Supplementary Table S1 online). To validate our in silico find-
ings, we performed quantitative real-time reverse tran-
scriptaseePCR (see Supplementary Figure S1 online). The
variability in gene expression within groups is supplied in
Supplementary Figure S2 online. Heatmap and clustering an-
alyses based on gene expression levels show clear variations
between AD patients and control subjects, regardless of FLG
status (see Supplementary Figures S3 andS4online). In contrast,
there were no significant differences between AD FLG MUT
patients and ADWT/WT patients according to statistical anal-
ysis using DESeq2 and as illustrated in Supplementary
Figures S3 and S4. One patient with AD FLG MUT displayed
an atypical gene expression profile when compared with other
AD patients that could not be explained by FLG genotype or by
other parameters including sex, age, serum IgE level, EczemaArea and Severity Index (EASI) score, and differential blood
counts (see Supplementary Figures S3 and S4, and data not
shown). The gene expression profile of the skin of two IV pa-
tients was similar to that of AD patients whereas others (n ¼ 5)
were similar to the control profile (see Supplementary
Figures S3 and S4). This was not dependent on the type of
FLGmutations. Therefore, FLGmutations do not determine the
gene expression signature in the skin of AD or IV patients.
The machinery for RNA and protein synthesis is enhanced in
AD and IV skin
To identify specific genes that are differentially modulated in
various disease groups, we compared all groups by using an
adjusted P (false discovery rate) of less than 0.1 and a change
in gene expression greater than 2-fold. We found 607
differentially expressed genes (476 up-regulated and 131
down-regulated) when all AD patients (n ¼ 13) were
compared with control subjects (n ¼ 9) (see Supplementary
Tables S3 and S4 online), 618 differentially expressed genes
(489 up-regulated and 129 down-regulated) when AD WT/
WT patients (n ¼ 7) were compared with control volunteers
(n ¼ 9) (see Supplementary Tables S3eS5 online), and 193
differentially expressed genes (172 up-regulated and 21
down-regulated) when IV patients (n ¼ 7) were compared
with control volunteers (n ¼ 9) (see Supplementary
Tables S3eS6 online). No significant differences were found
when comparing AD WT/WT with AD FLG MUT patients
(see Supplementary Table S3). Overall gene ontology (GO)
and pathway analyses are summarized in Table S8 online.
They showed that the cellular machineries involved in RNA
transcription, splicing, and processing as well as in protein
translation and elongation were significantly up-regulated in
all AD skin classes compared with control samples
(Figure 1aec, and see Supplementary Table S4). Consistent
with this, the expression of genes involved in metabolism of
proteins was enhanced as well (Figure 1d and e, and see
Supplementary Table S4). Results of in silico protein network
analysis of the up-regulated genes related to RNA and protein
metabolism are shown in Figure 1b and 1d, respectively.
Increased protein metabolism and turnover were further
shown by an increase in ubiquitination processes (see
Supplementary Figure S5 online). Moreover, GO and network
analyses showed increased RNA and protein metabolism also
in the skin of IV patients when compared with control sub-
jects, although the extent of up-regulation was not as high as
that observed in the skin of AD patients (Figure 1c and e, and
see Supplementary Tables S6 and S7 and Supplementary
Figure S6 online). Accordingly, ubiquitination was not
induced in IV skin (see Supplementary Tables S6eS8 online).
Thus, there seems to be a progression of up-regulation of
cellular metabolism in the skin, from IV to AD patients, that is
associated with impaired epidermal barrier function and is
further triggered by inflammation.
ATP synthesis-related genes are enhanced in AD and IV skin
GO analyses comparing all AD patients with healthy control
subjects showed up-regulated expression of key genes
involved in adenosine (ATP) synthesis (Figure 2a and b),
consistent with the high energy demand of RNA and protein
synthesis. Genes of ATP synthesis were up-regulated in AD
patients (Figure 2b, and see Supplementary Tables S4, S5,www.jidonline.org 99
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Figure 1. Expression of genes encoding machinery for RNA and protein synthesis is enhanced in AD and IV skin. Network analysis of genes differentially
expressed in all AD patients (including those with and without FLG loss-of-function mutations) compared with healthy control subjects. Genes were included in
analyses as defined by FC > 2 and adjusted P < 0.1. (a) Expression of genes involved in RNA machinery in the skin of all AD patients versus healthy donors.
(b) Thirty-two selected genes were classified into the RNA machinery category with the GO terms Gene expression, RNA binding, RNA splicing, RNA
processing, mRNA processing, RNA metabolic process, mRNA metabolic process, Spliceosome, Processing of Capped Intron-Containing Pre-mRNA, and
ncRNA processing. (c) Histograms show changes in expression of FUS and POLR2G. (d) Twenty-six selected genes were classified into the protein machinery
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Figure 2. Expression of ATP synthesis-related genes is enhanced in AD and IV skin. Network analysis of genes differentially expressed in all AD patients
(including those with and without FLG loss-of-function mutations) compared with healthy control subjects. Genes were included in analyses as defined by
FC > 2 and adjusted P < 0.1. (a) Twenty-nine genes were classified into the ATP synthesis category with the GO terms ATP synthesis coupled electron transport,
Mitochondrial proton-transporting ATP synthase complex, ATP biosynthetic process, and Generation of precursor metabolites and energy. (d) Histograms
show changes in expression of COX6C, ENO1, NDUFV1, and ATP5E. Data were analyzed using a one-way analysis of variance test followed by a Newman and
Keuls post hoc test. **P < 0.01, ***P < 0.0001. Healthy control subjects are designated as Ctrl WT/WT, patients with AD without FLG-null mutations as
AD WT/WT, AD patients with FLG-null mutations as AD FLG MUT, and IV patients as IV. AD, atopic dermatitis; ATP, adenosine triphosphate; Ctrl, control; FC,
fold changes; FLG, filaggrin; GO, gene ontology; IV, ichthyosis vulgaris; MUT, mutated; WT, wild type.
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RNA Sequencing in AD and IV Skinand S8) and in IV patients when compared with control
subjects, yet to a lesser extent than in AD (Figure 2b, and see
Supplementary Tables S6eS8). Genes involved in fatty acid
(FA) metabolism were up-regulated, including ACAA1,
ECHDC2, FABP4, SLC27A3, and ECHS1, as were genescategory with the GO terms Translational elongation, Translation, Metabolism o
in expression of EIF1B and 3K EIF3K. Data were analyzed using a one-way analy
**P < 0.01, ***P < 0.0001. Healthy control subjects are designated as Ctrl WT/W
patients with FLG-null mutations as AD FLG MUT, and IV patients as IV. AD, at
ontology; IV, ichthyosis vulgaris; MUT, mutated; WT, wild type.
=related to cholesterol biosynthesis such as TM7SF2 and
CYP5R1 in AD patients when compared with control subjects
(Figure 3a and b, and see Supplementary Tables S4 and S5).
Moreover, genes of arachidonic, linoleic, and a-linolenic
acid metabolism were triggered in AD but not in IV patientsf proteins, and Protein metabolic processes. (e) Histograms show changes
sis of variance test followed by a Newman and Keuls post hoc test. *P < 0.05,
T, patients with AD without FLG-null mutations as AD WT/WT, AD
opic dermatitis; Ctrl, control; FC, fold changes; FLG, filaggrin; GO, gene
www.jidonline.org 101
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Figure 3. Expression of genes related to lipid metabolism is enhanced in AD and IV skin. Network analysis of genes differentially expressed in all AD
patients (including patients with and without FLG loss-of-function mutations) compared with healthy control subjects. Genes were included in analyses as
defined by FC > 2 and adjusted P < 0.1. (a) Thirteen genes were classified into the lipid metabolism category with the GO terms Lipid metabolic process,
Fatty acid metabolic process, Cellular lipid catabolic process, Small molecule metabolic process, and Lipid biosynthetic pathways. (b) Histograms show changes
in expression of FABP4, ECHDC2, SLC27A3, andNDUFAB1. (c) Thirteen genes were classified into the lipid catabolism category with the GO terms Arachidonic
metabolism, Linoleic acid metabolism, Alpha-linolenic acid metabolism and Catabolic process. (d) Histograms show changes in expression of PLA2G2F and
PLA2G3. Data were analyzed using a one-way analysis of variance test followed by a Newman Keuls post hoc test. *P< 0.05, **P< 0.01, ***P< 0.0001. Healthy
control subjects are designated as Ctrl WT/WT, patients with AD without FLG-null mutations as AD WT/WT, AD patients with FLG-null mutations as AD FLG
MUT, and IV patients as IV. AD, atopic dermatitis; Ctrl, control; FC, fold changes; FLG, filaggrin; GO, gene ontology; IV, ichthyosis vulgaris; MUT, mutated; WT,
wild type.
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102(Figure 3c and d, and see Supplementary Tables S7 and S8),
as suggested earlier in epidermal equivalents generated with
patient keratinocytes (Blunder et al., 2017). Moreover, the
expression of genes related to FA metabolism (FABP4,
TM7SF2, ACAA1, NDUFAB1) was less induced in IV skin
than in AD skin (Figure 3, and see Supplementary
Tables S4eS7). In summary, RNA and protein synthesis that
both require enhanced ATP production likely via FA catab-
olism is enhanced in AD skin at a higher rate than in IV skin.
Cell death is promoted in nonlesional AD and IV skin
Comparison of AD patients with control subjects shows
enhanced expression of key genes involved in apoptosis and
cell death (Figure 4a, and see Supplementary Tables S4 and
S5). In IV, expression of cell death genes was moderately
altered (BLCAP, PDCD6, TNFRSF25, NGFRAP1, TRADD)
when compared to control subjects and to AD patients
(Figure 4, and see Supplementary Tables S6eS8). Cell deathJournal of Investigative Dermatology (2018), Volume 138can result from various cellular abnormalities including DNA
damage, oxidative stress, or elevated levels of extracellular
ATP. Increased oxidative stress has been shown in AD (Nakai
et al., 2009; Tsukahara et al., 2003), thereby triggering anti-
oxidative cellular responses via multiple pathways
(Rinnerthaler et al., 2015). Expression of genes conferring
resistance to oxidative stress (ATOX1, GSTP1, GPX4, PRDX5,
RNF7) was increased in the skin of AD patients (Figure 4b, and
see Supplementary Tables S4 and S5), and to a lesser extent in
the skin of IV patients compared with control subjects or with
AD patients (Figure 4b, and see Supplementary Tables S6 and
S7). Thus, we here show that the transcriptional response to
oxidative stress is not only significantly triggered in the skin of
AD patients but also of IV patients. Expression of DNA dam-
age/repair genes (RAD9A, CIRBP, RBX1, UBA52, UBB,
UBE2B, POLD4, DDIT4, MUM1) was up-regulated in AD
patients and, to a lesser degree, in IV patients (RAD9A,UBA52,
DDIT4, MUM1) when compared with control subjects or with
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Figure 4. Expression of genes related to cell death, oxidative stress, DNA damage/repair, and autophagy is enhanced in AD and IV skin. Network analysis
of genes differentially expressed in all AD patients (including patients with and without FLG loss-of-function mutations) compared with healthy control
subjects. Genes were included in analyses as defined by FC > 2 and adjusted P < 0.1. (a) Twenty-one selected genes were classified into the apoptosis
category with the GO terms Apoptotic process, Cellular response to stimulus, and Apoptosic signaling pathway. Histograms show changes in expression
of IFI27, HRAS, PDCD6, and TNFRSF25. Histograms show changes in expression of ATOX1, GPX4, GSTP1, and PRDX5. (b) CIRBP, RAD9A, POLD4, and
UBB. (c) ATG4D, FIS1, ULK1, and TMEM208. (d) Data were analyzed using a one-way analysis of variance test followed by a Newman Keuls post hoc test
*P < 0.05, **P < 0.01, ***P < 0.0001. Healthy controls are designated as Ctrl WT/WT, patients with AD without FLG null mutations as AD WT/WT, AD
patients with FLG null mutations as AD FLG MUT, and IV patients as IV. AD, atopic dermatitis; Ctrl, control; FLG, filaggrin; GO, gene ontology; IV, ichthyosis
vulgaris; MUT, mutated; WT, wild type.
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Figure 5. Xenobiotic metabolism is triggered in AD but not in IV skin. Network analysis of genes differentially expressed in all AD patients (including patients
with and without FLG loss-of-function mutations) compared with healthy control subjects. Genes were included in analyses as defined by FC > 2 and adjusted
P < 0.1. (a) Thirteen selected genes were classified into the xenobiotic metabolism category with the GO terms Xenobiotic metabolic process, Xenobiotic
glucuronidation, Cellular response to chemical stimulus, Pigment metabolic process, Small molecule metabolic process, and Drug metabolic process.
(b) Histograms show changes in expression of UGT1A7, UGT1A9, UGT1A10, CYP4F12, and CYP2E1. (c) Histograms show changes in expression of UGT1A7,
UGT1A9, UGT1A10, CXP4F12, and CYP2E1 in the skin of patients from cohort II. Data were analyzed using a one-way analysis of variance test followed by
a Newman and Keuls post hoc test. *P < 0.05, **P < 0.01, ***P < 0.0001. Healthy control subjects are designated as Ctrl WT/WT, patients with AD
without FLG-null mutations as ADWT/WT, AD patients with FLG-null mutations as AD FLGMUT, and IV patients as IV. AD, atopic dermatitis; Ctrl, control; FC,
fold changes; FLG, filaggrin; GO, gene ontology; IV, ichthyosis vulgaris; MUT, mutated; WT, wild type.
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Programmed cell death, oxidative stress, and repair mecha-
nism induce autophagy. The up-regulation of autophagy-
related genes such as ATG16L2, FIS1, ATG4s, ULK1,
TMEM208, S1008, and S100A9was only observed in AD skin
(Figure 4d, and see Supplementary Tables S4eS7). These re-
sults indicate that cell death, oxidative stress, DNA damage,
and autophagy are enhanced in nonlesional AD, regardless of
FLG-null mutation status and only marginally in IV.
Xenobiotic metabolism is triggered in AD but not in IV skin
Further analyses of the acquired results showed unexpected
data on xenobiotic metabolism. Genes involved in the pro-
cessing of xenobiotics, pollutants, and endocrine disruptors
were up-regulated in the skin of AD patients (Figure 5 a and b,
and see Supplementary Tables S4 and S5). Specifically, genes
implicated in xenobiotic glucuronidation were inducedJournal of Investigative Dermatology (2018), Volume 138(Figure 5a and b, and see Supplementary Tables S4 and S5).
Hence, the expression of key genes involved in skin detoxifi-
cation is enhanced in AD patients, independent of FLG status.
In contrast, the expression of xenobiotic metabolism genes
remained unaltered in the skin of IV patients compared with
control subjects (Figure 5b, and see Supplementary Table S6).
Thus, up-regulation of xenobioticmetabolism key genes seems
to be specific for AD skin (Figure 5b, and see Supplementary
Tables S7 and S8). To further validate these data, we per-
formed additional quantitative real-time reverse tran-
scriptaseePCRon skin biopsy samples fromadistinct cohort of
patients (cohort II). Similar to RNA sequencing analysis, in this
second cohort of patients we observed a global increase in the
expression of UGT1A7, UGT1A9, UGT1A10, CYP2E1, and
CYP4F12 in the skin of patients with AD, in contrast to healthy
control subjects and IV patients (Figure 5c). Thus, these data
suggest that inflammation, but not defective epidermal barrier
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otics, pollutants, and endocrine disruptors in the skin of AD
patients. Hence, one can hypothesize that the transition from
subinflammatory, dry and scaly skin to overt inflamed skin
might be related to triggered local metabolism of noxious
molecules, as suggested in other work (Acciani et al., 2013;
Hidaka et al., 2017; Kabashima et al., 2016; Kim 2015;
Miller and Peden, 2014).
Further insights from gene profiling comparison of AD and
IV skin
Genes involved in keratinocyte differentiation, including the
S100A, KRT, and SPPR families, were induced in AD but not
in IV, similarly to the expression of genes involved in im-
munity (CCL13, CCL18, CCL27, B2M, S100A8, S100A9,
IFI27, IFR3, LCN2) (see Supplementary Table S7). Several
genes that were down-regulated specifically in AD are
related to inflammation (IL1F8, ADIPOQ, KDM6B) and to
apoptosis (CSRNP3, G2E3, MTRNR2L4, PEG3) (see
Supplementary Table S7). Thus, epidermal homeostasis is
more altered in AD than in IV, suggesting that counteracting
responses are not sufficient to dampen ongoing inflammation
and to normalize the keratinization process.
DISCUSSION
The skin is in daily contact with foreign compounds that are
potentially harmful. Endocrine disruptors, pollutants, pesti-
cides, and other chemicals are found in water but also in skin
care products such as shampoos and cosmetics. The skin of
patients with AD is more reactive to these compounds and
more prone to develop irritation after exposure to chemicals
(Al-Jaberi and Marks, 1984). Moreover, increased concen-
trations of air pollutants are positively associated with AD,
and the levels of endocrine disruptors such as phthalates are
elevated in the dust collected from the bedrooms of children
with AD (Ahn, 2014; Hidaka et al., 2017; Kabashima et al.,
2016). Furthermore, recent work has shown the presence of
metabolites generated by phase II enzymes in the skin,
including glucuronides of drugs and pollutants (Manevski
et al., 2015). These molecules are capable of inducing
epigenetic modifications that promote deregulated immunity
associated with a T helper type 2/T helper 17 immune
response, higher serum IgE levels, and increased numbers of
activated dendritic cells in the lungs (Acciani et al., 2013;
Kim, 2015; Miller and Peden, 2014). Previous studies using
photoacoustic spectrometry have shown that the skin of AD
patients is more permeable to both hydrophilic and hydro-
phobic chemicals compared with the skin of healthy donors
(Hata et al., 2002). The penetration of hydrophilic com-
pounds into the skin correlates with both the severity of AD
symptoms and serum IgE levels (Hata et al., 2002). Thus,
several lines of evidence strongly suggest a link between AD
and xenobiotics. Our results support this hypothesis. We
found increased expression of several key genes involved in
xenobiotic metabolism, including uridine-5’-diphospho
(UDP)-glucuronosyltransferases (UGTs), in the skin of AD
patients from two distinct cohorts, regardless of their FLG
mutation status (Figure 5, and see Supplementary Tables S4
and S5). UGTs are a family of membrane-bound enzymes
expressed in various tissues, including human skin, thatcatalyze the transfer of the glucuronic acid moiety of UDP-
glucuronic acid to a large number of endogenous and
exogenous compounds (Sumida et al., 2013). We show here
that AD is associated with increased expression of
glucuronidation-related genes in the skin. Thus, these results
support previous work suggesting a link between AD and
exposure to pollutants/xenobiotics (Ahn, 2014; Hidaka et al.,
2017; Jedrychowski et al., 2011; Kabashima et al., 2016; Kim
et al., 2013; Kim, 2015; Miller and Peden, 2014). In contrast
to AD, expression of UGT1As and other genes involved in
pollutant metabolism remained unchanged in the skin of IV
patients (Figure 5, and see Supplementary Tables S4eS8).
Whereas epidermal barrier function is compromised in both
IV and AD patients, only AD skin exhibits activated pathways
involved in pollutant detoxification. Thus, it can be assumed
that impaired barrier function because of FLG null mutations
does not, per se, render the skin more permeable to envi-
ronmental pollutants. In line with our RNA sequencing data,
increased levels of xenobiotics were detected in the serum of
AD patients (Kim, 2015; Miller and Peden, 2014). Because
enhanced xenobiotic metabolism is only observed in AD and
not in IV, one can hypothesize that this might be a conse-
quence of the inflammation and not its cause. However, up-
regulation of key genes involved in drug, pollutants, or
chemical metabolism has never been reported in psoriasis,
another common inflammatory skin disease, thus likely
ruling out this hypothesis (Coda et al., 2012; Keermann et al.,
2015; Ko˜ks et al., 2016; Li et al., 2014; Szabo´ et al., 2014).
Therefore, we suggest that enhanced xenobiotic metabolism
in the skin of individuals predisposed to AD triggers skin
inflammation and is thus critically involved in the develop-
ment of AD (Acciani et al., 2013; Hidaka et al.,
2017; Kabashima et al., 2016; Kim, 2015; Miller and
Peden, 2014).
Excess water loss through the skin in AD and IV (Gruber
et al., 2011) induces compensatory mechanisms such as
epidermal hyperplasia to restore the stratum corneum (SC) to
limit excess transepidermal water loss and heat loss (Proksch
et al., 1993). Keratinocyte hyperproliferation requires
increased synthesis of DNA, RNA, and proteins, and thus
energy provided by ATP. Accordingly, we observed in both
AD and IV patient skin increased expression of several key
genes involved in RNA and protein synthesis, modification
and turnover, and ATP synthesis and transport (Figures 1 and
2, and see Supplementary Tables S4eS6). This profile of
enhanced metabolism is not directly linked to FLG-null
mutations, because AD WT/WT patients exhibit similar gene
expression patterns (Figures 1 and 2, and see Supplemental
Tables S4 and S5). Oxidation of FAs that originate from
various pools is a major generator of cellular ATP. Because
FABP4 and SCL27A3 were up-regulated in the skin of AD
patients (Figure 3a, and see Supplementary Tables S4 and S5),
we postulate that the high demand for ATP in AD skin,
regardless of FLG mutation status, requires the mobilization
of FAs from both adipose tissue and intracellular pools. In line
with this, we found increased expression of genes involved in
FA synthesis (ACCA1, ECHDC2) in the skin of AD patients
(Figure 3a, and see Supplementary Tables S4 and S5). Thus, in
AD, we speculate that FAs, including structural FAs, are used
as substrates to produce ATP to provide energy forwww.jidonline.org 105
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showing reduced long-chain ceramides in the stratum cor-
neum of AD patients, suggesting that they may serve as
substrates for ATP production (Cole et al., 2014; Janssens
et al., 2012). In the skin of IV patients, genes of the FA
metabolism were up-regulated, yet to a lesser extent than in
AD (see Supplementary Tables S6 and S7). Thus, impaired
epidermal barrier rather than inflammation induces increased
cellular metabolism in the epidermis and subsequent
deregulated FA metabolism, potentially sustaining abnormal
stratum corneum FA composition. Moreover, the expression
of genes involved in the metabolism of arachidonic, linoleic,
and a-linolenic acid is only triggered in AD skin (Figure 3c
and d, and see Supplementary Tables S4eS7), which may
promote de-regulated keratinocyte differentiation and local
inflammation (Blunder et al., 2017). Receptors controlling
xenobiotic metabolism such as aryl hydrocarbon receptor,
pregnane x receptor, and peroxisome proliferator-activated
receptor also control the expression of genes involved in FA
metabolism including CYP2E1, CYP4F12, UGT1As, S100A9,
and PLA2s (Barbier et al., 2003; Beck et al., 2003; Buckley
and Klaassen, 2009). Thus, xenobiotic metabolism may
interfere with arachidonic, linoleic, and a-linolenic acid
metabolism, hereby sustaining abnormal lipid metabolism,
altered keratinization, and inflammation as observed in AD.
Previous studies reported increased expression of pro-
apoptotic genes in the skin of AD patients associated with
deregulated protein metabolism, and it is widely accepted that
keratinocyte apoptosis is a major cause for spongiosis in
lesional AD (Rebane et al., 2012). Here, we found enhanced
expression of genes involved in cell death not only in the
nonlesional skin of AD patients, regardless of FLG status, but
also in the skin of IV patients, although more moderately
(Figure 4a, and see Supplementary Tables S4eS8). Increased
cell death in IVand in AD ismediated via both the intrinsic and
extrinsic pathways (Figure 4a, and see Supplementary
Tables S4eS7). Increased apoptosis observed in AD seems to
originate from multiple cell death pathways, including
oxidative stress and the IFN-g and TNF-a signaling pathways
(Rebane et al., 2012). Expression of IFI27, which encodes a
protein that mediates IFN-induced apoptosis via the release of
cytochromeC from themitochondria and the activation of BAX
and caspases 2, 3, 6, 8, and 9, is enhanced in AD skin, as re-
ported previously (Cole et al., 2014), but not in IV skin
(Figure 4a, and see Supplementary Tables S4eS7). The
response to oxidative stress is markedly up-regulated in AD
and moderately in IV (Figure 4b, and see Supplementary
Tables S4eS7). Increased oxidative stress has already been
observed in AD patients, including young children (Peroni
et al., 2012; Tsuboi et al., 1998; Tsukahara et al., 2003).
DNA damage can be induced by oxidative stress and leads to
the up-regulation of genes involved in DNA repair as observed
in AD skin and, to a lesser degree, in IV skin (Figure 4c, and see
Supplementary Tables S4eS8). Thus, cell death, oxidative
stress, DNA damage, and resulting autophagy are more pro-
nounced in AD skin than in IV skin (Figure 4, and see
Supplementary Tables S4eS8), similar to cellular metabolism
and ATP production, suggesting a causal relationship. More-
over, the metabolism of xenobiotics not only generates dele-
terious metabolites but also by-products such as reactiveJournal of Investigative Dermatology (2018), Volume 138oxygen species in the skin (Slominski et al., 2012). Thus, high
cellular metabolism coupled with the metabolism of pollut-
ants, endocrine disruptors, or other noxious chemicals in the
skin may favor AD via reactive oxygen species production and
deregulated lipid metabolism.
In conclusion, this work comparing the transcriptome
profiles of nonlesional skin from AD patients to the skin of IV
patients and of healthy control subjects uncovers a new po-
tential pathogenic pathway involved in AD. Increased drug,
pesticide, chemical, and endocrine disruptor metabolism in
the skin, resulting from systemic or topical exposure, might
trigger oxidative stress and abnormal lipid metabolism,
especially, arachidonic, linoleic, and a-linolenic acid meta-
bolism, hereby reaching a threshold favoring the transition
from dry and scaly to inflamed AD skin. However, the
complete mechanism remains to be elucidated.
METHODS
RNA sequencing
RNA extraction and quality control is described in the
Supplementary Methods online. 50 ng of total RNA were amplified
by applying the Ovation RNA-Seq System V2 (NuGen, Emeryville,
CA). The resulting cDNAs were pooled in equal amounts and used to
prepare the DNA fragment library with SOLiD System chemistry
(Life Technologies, Carlsbad, CA). Sequencing was performed using
the SOLiD 5500W platform and DNA sequencing chemistry (Life
Technologies). Raw reads (75 base pairs) were color-space mapped
to the human genome hg19 reference using the Maxmapper algo-
rithm implemented in the Lifescope software (Life Technologies).
Mapping to multiple locations was permitted. Reads with a score
less than 10 were excluded. Average mapping quality was 30.
Analysis of the RNA content and gene-based annotation was done
with the whole-transcriptome workflow of Lifescope.
Data analysis
To identify significantly differentially expressed genes between patient
groups, non-normalized mapped raw counts were used and analyzed
using the R package DESeq2, which is based on a negative-binomial
distribution. Two different group comparisons were performed: (i)
comparison of AD, IV, and control samples and (ii) comparison of
patient groups with FLG mutation status included: these are AD pa-
tients without FLG mutation (AD WT/WT), AD patients with FLG
mutation (AD FLG MUT), IV patients, and control samples (Ctrl WT/
WT). Different sequencing runs were considered by including a batch
variable in the respective design. Genes with a mean of mapped reads
greater than10were considered for further analyses. For comparison of
more than two groups, likelihood ratio tests were performed; for pair-
wise group comparison, negative binomialWald testswere performed.
P-valueswere adjusted formultiple testing based on the false discovery
rate according to the Benjamini-Hochbergmethod.Geneswith at least
a 2-fold change and an adjusted P-value less than 0.1 were considered
as significantly differentially expressed. GO and pathways analyses
were performed using the tool DAVID (Huang da et al., 2009) and
ConsensusPathDB (Kamburov et al., 2011). Functional protein asso-
ciation networks were constructed using STRING based on the lists of
differentially expressed genes (Szklarczyk et al., 2015). For further
analysis (i.e., the principal component analysis) the remove Batch
Effect of the R package limma on the regularized log-transformed
normalized data were used. Heatmaps were visualized and hierar-
chical clustering analysis with average linkage were performed using
S Blunder et al.
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patient samples. Only variable genes with interquartile range greater
than 0.8 were considered.
Statistical analysis
Statistical analyses for gene expression validation were performed
using GraphPad Prism 6 software (GraphPad Software, La Jolla, CA).
Data are presented as mean  standard error of the mean. Statistical
significance was determined between groups using an one-way
analysis of variance test followed by a Newman and Keuls post
hoc test with *P < 0.05, **P < 0.01, ***P < 0.0001.
The study was approved by the Ethics Committee of the Medical
University of Innsbruck and conducted in accordance with the
Declaration of Helsinki principles. All study subjects gave written
informed consent and participated voluntarily.
Data have been preceded and are now deposited in a public re-
pository with an accession number (GSE102628). The entries are
scheduled to be released on Nov 03, 2017.
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